PharmaCyte Biotech, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of treatments for cancer and diabetes. The company is headquartered in Las Vegas, Nevada and currently employs 2 full-time employees. The company went IPO on 2003-09-11. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable, non-metastatic pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
PharmaCyte Biotech Inc 주요 수익원은 Power and Gas이며, 최신 수익 발표에서 수익은 179,331,000입니다. 지역별로는 North America이 PharmaCyte Biotech Inc의 주요 시장이며, 수익은 502,520,000입니다.
PharmaCyte Biotech Inc은 수익성이 있나요?
no, 최신 재무제표에 따르면 PharmaCyte Biotech Inc의 순손실은 $0입니다.